Cable Hill Partners’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Cable Hill Partners’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1	Closed	–	–	992
2017 Q4	$0	Buy	+1	New	+$128	﹤0.01%	1054

Other funds holding TTPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Cable Hill Partners's TTPH Position: Q1 2018 in Review

Cable Hill Partners sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q1 2018, closing a stake of 1 share.

Cable Hill Partners first reported a position in TTPH in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 94 funds tracked by Wall St. Rank hold TTPH as of Q1 2018.

Cable Hill Partners reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Cable Hill Partners sold 1 Tetraphase Pharmaceuticals, Inc. share in Q1 2018.
Cable Hill Partners first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2017 and held it in 1 quarter.
Cable Hill Partners's Tetraphase Pharmaceuticals, Inc. position peaked at $0 in Q4 2017.
94 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q1 2018.

Based on Cable Hill Partners's 13F filing for Q1 2018, filed 20 Apr 2018.